Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Efficacy and safety of PRK in adult patients with anisometropic amblyopia

Poster Details

First Author: A. Roszkowska ITALY

Co Author(s):    A. Signorino   C. Cali   M. Urso   P. Aragona           

Abstract Details

Purpose:

To evaluate the visual and refractive outcome of photorefractive keratectomy in adult patients with anisometropic amblyopia.

Setting:

Ophthalmology Unit of University of Messina, Italy.

Methods:

Sixty two subjects with unilateral anisometropic amblyopia treated with photorefractive keratectomy were enrolled to the study. The patients were divided into 3 groups, accordingly to refractive error. First group included 29 eyes with myopia, the second group was composed by 22 eyes with hyperopia and the third by 11 eyes with high astigmatism. Follow-up was of 12 to 24 months after the treatment. The mean outcome measures were the uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), refraction and corneal transparency.

Results:

In the first group the UCVA changed from 0,06±0,07 to 0,8±0,22 and the BCVA from 0,52±0,1 to 0,84±0,18. 91,9% of eyes improved their BCVA. No eye lost lines of the BCVA. In the second group the UCVA changed from 0,17±0,14 to 0,8±0,2 and the BCVA from 0,53±0,14 to 0,97±0,07. 87% of eyes improved their BCVA. No eye lost lines of the BCVA. In the third group the UCVA changed from 0,1±0,11 to 0,83±0,23 and the BCVA from 0,48±0,1 to 0,98±0,04. 84% of eyes improved their BCVA of 1 or more lines. 1,61% lost 1 line of the BCVA.

Conclusions:

This study shows as the excimer laser refractive surgery appears to be a safe and efficient procedure in the treatment of anisometropic amblyopia in adults. The adult patients with anisometropic amblyopia may benefit from the refractive treatment and a very good visual and refractive outcome can be expected.

Financial Disclosure:

NONE

Back to Poster listing